Gufic Biosciences Limited (Gufic) have received approval from the Drug Controller General of India (DCGI) for both Dalbavancin API and Formulation which shall be used in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adult patients caused by susceptible isolates of certain Gram-positive microorganisms Dalbavancin was developed with a purview of improved alternative to the currently available glycopeptides like Teicoplanin and Vancomycin, which are common intravenous agents for ABSSSI associated with Methicillin Resistant Staphylococcus aureus (MRSA). This molecule will add value to therapeutic armamentarium in Gufic's anti-microbial portfolio. Additionally, Gufic has applied for a process patent for the injection formulation of Dalbavancin in India.